Total revenue for the three months to January 31 was $357m, up 7 per cent on the comparable quarter in fiscal 2011. Sales to the biopharmaceutical sector rose 12.3 per cent to $201.6m with – according to Pall – growth being seen in its systems, consumables and laboratory businesses.
Larry Kingsley, president and CEO, said: “The sales increase in the quarter reflects good growth in both the Life Sciences and Industrial segments. On a global basis, emerging market sales grew over 20 per cent in local currency driven by the Energy markets in MENA and Latin America.”
For the second quarter Pall expects the market to be more challenges – predicting a slowdown in sales and some negative impact from its recent acquisition of analysis instrumentation firm ForteBio.
“While we expect some EPS headwind in the second half as sales growth moderates and foreign exchange impacts our consolidated results, we should be able to offset most of the impact with cost and productivity actions underway. The previously announced ForteBio acquisition closed last week. That will be slightly dilutive to our 2012 results.